Literature DB >> 30373773

The AB loop of oncostatin M (OSM) determines species-specific signaling in humans and mice.

Juan M Adrian-Segarra1, Krishnamoorthy Sreenivasan1, Praveen Gajawada1, Holger Lörchner1,2, Thomas Braun3,2, Jochen Pöling4,2.   

Abstract

The pleiotropic interleukin-6 (IL-6)-type cytokine oncostatin M (OSM) signals in multiple cell types, affecting processes such as cell differentiation, hematopoiesis, and inflammation. In humans, OSM exerts its effects through activation of either of two different heterodimeric receptor complexes, formed by glycoprotein 130 (gp130) and either OSM receptor (OSMR) or leukemia inhibitory factor receptor (LIFR). In contrast, the mouse OSM orthologue acts mainly through dimers containing OSMR and gp130 and shows limited activity through mouse LIFR. Despite their structural similarity, neither human nor mouse OSM signal through the other species' OSMR. The molecular basis for such species-specific signaling, however, remains poorly understood. To identify key molecular features of OSM that determine receptor activation in humans and mice, we generated chimeric mouse-human cytokines. Replacing regions within binding site III of murine OSM with the human equivalents showed that the cytokine's AB loop was critical for receptor selection. Substitutions of individual amino acids within this region demonstrated that residues Asn-37, Thr-40, and Asp-42 of the murine cytokine were responsible for limited LIFR activation and absence of human OSMR/LIFR signaling. In human OSM, Lys-44 appeared to be the main residue preventing mouse OSMR activation. Our data reveal that individual amino acids within the AB loop of OSM determine species-specific activities. These mutations might reflect a key step in the evolutionary process of this cytokine, in which receptor promiscuity gives way to ligand-receptor specialization.
© 2018 Adrian-Segarra et al.

Entities:  

Keywords:  LIFR; OSM; OSMR; STAT3; cell signaling; cytokine; oncostatin M; protein-protein interaction; signal transduction

Mesh:

Substances:

Year:  2018        PMID: 30373773      PMCID: PMC6311520          DOI: 10.1074/jbc.RA118.004375

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  61 in total

1.  NCBI's LocusLink and RefSeq.

Authors:  D R Maglott; K S Katz; H Sicotte; K D Pruitt
Journal:  Nucleic Acids Res       Date:  2000-01-01       Impact factor: 16.971

2.  The metapopulation genetic algorithm: An efficient solution for the problem of large phylogeny estimation.

Authors:  Alan R Lemmon; Michel C Milinkovitch
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-25       Impact factor: 11.205

3.  Oncostatin M and leukemia inhibitory factor do not use the same functional receptor in mice.

Authors:  M Ichihara; T Hara; H Kim; T Murate; A Miyajima
Journal:  Blood       Date:  1997-07-01       Impact factor: 22.113

4.  Construction and flow cytometric screening of targeted enzyme libraries.

Authors:  Navin Varadarajan; Jason R Cantor; George Georgiou; Brent L Iverson
Journal:  Nat Protoc       Date:  2009-05-21       Impact factor: 13.491

Review 5.  Haemopoietic receptors and helical cytokines.

Authors:  J F Bazan
Journal:  Immunol Today       Date:  1990-10

6.  DNAWorks: an automated method for designing oligonucleotides for PCR-based gene synthesis.

Authors:  David M Hoover; Jacek Lubkowski
Journal:  Nucleic Acids Res       Date:  2002-05-15       Impact factor: 16.971

7.  Dual oncostatin M (OSM) receptors. Cloning and characterization of an alternative signaling subunit conferring OSM-specific receptor activation.

Authors:  B Mosley; C De Imus; D Friend; N Boiani; B Thoma; L S Park; D Cosman
Journal:  J Biol Chem       Date:  1996-12-20       Impact factor: 5.157

8.  CLF associates with CLC to form a functional heteromeric ligand for the CNTF receptor complex.

Authors:  G C Elson; E Lelièvre; C Guillet; S Chevalier; H Plun-Favreau; J Froger; I Suard; A B de Coignac; Y Delneste; J Y Bonnefoy; J F Gauchat; H Gascan
Journal:  Nat Neurosci       Date:  2000-09       Impact factor: 24.884

9.  Purification to homogeneity and characterization of human B-cell differentiation factor (BCDF or BSFp-2).

Authors:  T Hirano; T Taga; N Nakano; K Yasukawa; S Kashiwamura; K Shimizu; K Nakajima; K H Pyun; T Kishimoto
Journal:  Proc Natl Acad Sci U S A       Date:  1985-08       Impact factor: 11.205

10.  SWISS-MODEL: modelling protein tertiary and quaternary structure using evolutionary information.

Authors:  Marco Biasini; Stefan Bienert; Andrew Waterhouse; Konstantin Arnold; Gabriel Studer; Tobias Schmidt; Florian Kiefer; Tiziano Gallo Cassarino; Martino Bertoni; Lorenza Bordoli; Torsten Schwede
Journal:  Nucleic Acids Res       Date:  2014-04-29       Impact factor: 16.971

View more
  7 in total

1.  Oncostatin M Receptor-Targeted Antibodies Suppress STAT3 Signaling and Inhibit Ovarian Cancer Growth.

Authors:  Anjali Geethadevi; Ajay Nair; Deepak Parashar; Zhiqiang Ku; Wei Xiong; Hui Deng; Yongsheng Li; Jasmine George; Donna M McAllister; Yunguang Sun; Ishaque P Kadamberi; Prachi Gupta; Michael B Dwinell; William H Bradley; Janet S Rader; Hallgeir Rui; Robert F Schwabe; Ningyan Zhang; Sunila Pradeep; Zhiqiang An; Pradeep Chaluvally-Raghavan
Journal:  Cancer Res       Date:  2021-08-11       Impact factor: 12.701

Review 2.  Oncostatin M, an Underestimated Player in the Central Nervous System.

Authors:  Evelien Houben; Niels Hellings; Bieke Broux
Journal:  Front Immunol       Date:  2019-05-29       Impact factor: 7.561

3.  Concomitant Activation of OSM and LIF Receptor by a Dual-Specific hlOSM Variant Confers Cardioprotection after Myocardial Infarction in Mice.

Authors:  Holger Lörchner; Juan M Adrian-Segarra; Christian Waechter; Roxanne Wagner; Maria Elisa Góes; Nathalie Brachmann; Krishnamoorthy Sreenivasan; Astrid Wietelmann; Stefan Günther; Nicolas Doll; Thomas Braun; Jochen Pöling
Journal:  Int J Mol Sci       Date:  2021-12-29       Impact factor: 5.923

Review 4.  The Role of Oncostatin M and Its Receptor Complexes in Cardiomyocyte Protection, Regeneration, and Failure.

Authors:  Thomas Kubin; Praveen Gajawada; Peter Bramlage; Stefan Hein; Benedikt Berge; Ayse Cetinkaya; Heiko Burger; Markus Schönburg; Wolfgang Schaper; Yeong-Hoon Choi; Manfred Richter
Journal:  Int J Mol Sci       Date:  2022-02-05       Impact factor: 5.923

5.  Patterns of Immune Activation in HIV and Non HIV Subjects and Its Relation to Cardiovascular Disease Risk.

Authors:  Alinda G Vos; Caitlin N Dodd; Eveline M Delemarre; Stefan Nierkens; Celicia Serenata; Diederick E Grobbee; Kerstin Klipstein-Grobusch; W D Francois Venter
Journal:  Front Immunol       Date:  2021-07-05       Impact factor: 7.561

6.  Molecular Simulation of Oncostatin M and Receptor (OSM-OSMR) Interaction as a Potential Therapeutic Target for Inflammatory Bowel Disease.

Authors:  Qingqing Du; Yan Qian; Weiwei Xue
Journal:  Front Mol Biosci       Date:  2020-03-04

Review 7.  Stimulation of Osteoclast Formation by Oncostatin M and the Role of WNT16 as a Negative Feedback Regulator.

Authors:  Pedro P C de Souza; Petra Henning; Ulf H Lerner
Journal:  Int J Mol Sci       Date:  2022-03-18       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.